MEGGLE brings Insights into distinguished Lactose Properties to Pharmaceutical Conference

Wasserburg, Germany: – Pharmaceutical Lactose and Excipients specialist MEGGLE GmbH & Co. KG (MEGGLE) will attend the upcoming 4^th European Conference on Pharmaceutics in Marseille, France as exhibitor and poster contributor.

MEGGLE’s stand (Booth 17) at the Marseille Chanot exhibition and convention center provides the company’s comprehensive range of value-added pharmaceutical grade lactose-based excipients.

MEGGLE’s promotion will preferentially focus on the potential of its excipients to support developers in the fields of inhalation (DPI), orally disintegrating tablet (ODT) formulations, as well as continuous manufacturing (CM) processes.

Expert Team

MEGGLE’s team at the tri-nationally organized conference will include Ricarda Leister, Head of R&D, and Dr. Franz Penz, Head of Innovation.

Ricarda Leister commented: “MEGGLE has not missed any European Conference on Pharmaceutics (ECP) since its existence, it provides a superb podium with specialist expertise to inform about our capabilities in excipients, to network with customers and partners from academia and industry, and to update the latest trends and innovations. MEGGLE remains loyal to ECP.”

Dr. Penz will show a poster based on his widespread interests in excipient stability. A broad range of commercially available Lactose grades from various manufacturers is subject to an unusual stress test mimicking harsh conditions for the most frequently used excipient in solid dosage form and inhalation. The work has been performed in collaboration with the University of Innsbruck at the chair of Pharmaceutical Technology (Prof. Dr. Ulrich Griesser), and is entitled “Various Pharmaceutical Lactose Grades in a Provocative Maillard Environment”

Investigating various Lactose grades within a Maillard Reaction

Commercially available Lactose clearly displays a distinct susceptibility within the investigated provocative Maillard system. The study precisely quantifies these non-enzymatic browning tendencies among a wide range of pharmaceutical Lactose grades as a reactive carbonyl entity and amino acid Lysine with its two molecular amino groups, as special reactant.

It was tried to establish a connection between the overall time-dependent reactivity and the crystallinity along with the particle morphology of the applied Lactose grade. In some cases a look into the impact of site-specific manufacturing processes was possible. Finally, an overall ranking in Lactose reactivity was set.

The results can be of utmost functional and pharmacological importance, as well as technological significance within Pharma, but also in nutrition industries. In daily formulation development assistance in choice of the right Lactose grade may be of interest, in existing challenging formulations alternative technical grades will be rapidly identified.

About MEGGLE Wasserburg

Bavarian-based MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About European Conference on Pharmaceutics 2023

First staged in 2018, the European Conference on Pharmaceutics brings together scientists from industry, academia and regulatory bodies worldwide to discuss research and development of drug products and medical devices, scale-up and pharmaceutical production.

The Conference provides a platform for both junior and established scientists from academia and industry from all over the world to present their work, network, discuss newest scientific findings and to share their experience with colleagues.

The 4^th European Conference is a two day event opening March 20 at the Marseille Chanot exhibition and convention center, part of the Palais des Congrés in the center of the historic Southern French seaport.

The conference theme covers a large range of presentations on fundamental research, formulation development, pharmaceutical ingredients, developing and processing equipment, analytical technologies, medicinal products, medical devices, contract manufacturing, regulatory frameworks, stability testing, in vitro-in vivo correlations, in-silico simulations and many others.

The event is jointly organised by Germany’s APV International Association for Pharmaceutical Technology), the French APGI International Society of Drug Delivery Sciences and Technology and Italy’s A.D.R.I.T.E.L.F Association of Italian Professors and Researchers of Pharmaceutical Technologies and Legislation Department of Pharmacy. Further information at:  https://www.europeanmeeting.org/home/